CD70 CXCR2-Modified CAR T-Cells Against Acute Myeloid Leukemia

Chimeric antigen receptor (CAR) T cells have not proven as effective in acute myeloid leukemia (AML) as they have in B-cell malignancies. Reasons for therapeutic failure include lack of tumor-specific targets, antigen loss, tumor heterogeneity, suppressive leukemic microenvironment, and poor CAR T cell fitness. Our group previously developed a novel CD70 CAR T cell modified to constitutively express the IL-8 receptor, CXCR2 (8R-70CAR T cell), to treat glioblastoma (IND#23881, Huang).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: John A Ligon, Paul Castillo, Xiaojie Ma, Linchun Jin, Haipeng Tao, Duy Nguyen, Gabriel Jobin, Olga Guryanova, Jatinder K Lamba, W Greg Sawyer, Duane Mitchell, Hector Mendez-Gomez, Elias Sayour, Jianping Huang Tags: 232 Source Type: research